P I Industries Ltd Q4 FY2022 Concall Summary

Key Takeaways

• Record quarter, guidance raised: Revenue grew 17% YoY and EBITDA jumped 34% to a record ₹305.6 cr, driven by strong export volumes and a domestic rebound. Management guided to 18-20% growth for FY23 with continued margin improvement.
• Margins expanded despite inflation: Gross margin rose 196 bps to 44% as favorable product mix and cost pass-through offset rising input costs, demonstrating pricing power and operational agility.
• Non-agchem diversification is accelerating: The CSM pipeline now has 40-plus products, over 20% from non-agchem (electronics, pharma), with 8 new customers added and inquiry rates doubling.
• Asset efficiency is a structural advantage: Asset turns already exceed 2x, well above the 1.75-2x industry benchmark, and management sees further scope to improve throughput without linear capex.
• What to watch next quarter: Whether the 6-7 planned CSM commercializations materialize, the pace of non-agchem scale-up, and how raw material inflation evolves through the kharif season.

Growth & Financial Performance

• Q4 revenue drivers: Export revenues grew 11% and domestic revenues surged 47% on a high base, with 7% from price increases and the balance from volume growth. Domestic performance was lifted by favorable rabi agro-climatic conditions and price hikes on key products.
• FY22 full-year picture: Revenue grew 16%, with exports up 20% and domestic up 4% (domestic had a 39% growth base in FY21 including the Isagro acquisition). EBITDA margin moderated 59 bps YoY as operating expenses rose 24% on higher fuel and utility costs, one-time strategic initiative spends, and COVID-related expenses.
• Margin resilience mechanics: The 196 bps gross margin expansion came partly from cost pass-through and partly from a shift in product mix: products at early lifecycle stages carry better margins than those further down the curve. The business mix change between domestic and export also contributed.
• Operating leverage ahead: Four new products commercialized in H2 FY22 carried initial inefficiencies; management expects to improve processes and costs on these in FY23, which combined with 20% topline growth should expand both gross and EBITDA margins.

Rajnish Sarna: "These differentials not necessarily come from the increase in the given products and their margins, change in product mix also contributes to the overall margin. And that is also important factor which has played out."

CSM Export Business & Diversification

• Inquiry pipeline surge: Significant new inquiries are coming from non-agchem spaces (electronics, pharma, others), with 8 new customers acquired. The pipeline holds 40-plus products at different development stages, more than 20% from non-agchem. Overall inquiry rates have doubled.
• Commercialization cadence: Three or four non-agchem projects were commercialized in FY22, though initial-year numbers are not significantly large. Management targets commercializing 6-7 molecules in FY23 and expects non-agchem to scale up meaningfully over the years.
• R&D infrastructure alignment: A significant number of projects and inquiries in R&D, particularly in the last 1-1.5 years, are from the non-agchem segment. R&D infrastructure is being aligned and created specifically for non-agchem molecules.
• Process innovation as a moat: Two new process innovations will be commercialized in FY23, one on an existing product and one on a new pipeline product. These help sustain businesses and ensure long-term customer stickiness.
• Pharma CDMO ambition: Management aims to build a differentiated CDMO model in pharma, with a roadmap that includes assets in India and a front-end in developed markets (US or Europe). M&A opportunities are being actively evaluated on both the CSM and API sides, in India and outside.
• Value chain progression: PI is moving up the value curve in non-agchem capabilities and offerings, though management acknowledges that parameters still need to improve.

Mayank Singhal: "Order book may not be the only the way it's good when you're in the initial stages of business. But I think once you're creating certain class of assets and capabilities for certain products, the stickiness is already created."

Domestic Business & Seasonality

• Q4 domestic breakout: Growth was led by new product introductions: a wheat herbicide doubled or tripled acreages and volumes, there was an aggressive push in horticulture, and the base was low (10-11% growth in Q4 FY21).
• Product launch momentum: Distruptor (an innovative insecticide for rice targeting brown planthopper) was successfully launched, along with three specialty fungicides for horticulture and rice, and new brands under Jivagro. Two patented insecticides and a broad-spectrum insecticide for chilli and cold crops are upcoming, plus a cotton herbicide this quarter. Sectin, an innovative nematicide and broad-spectrum fungicide, launched in the current fiscal year targeting horticulture.
• Kharif outlook: Management is witnessing a high swing in upcoming kharif, with acreage across cereals and oilseed marked as an increase. Given a normal monsoon forecast, the trend is bound to pick up. However, low pre-monsoon showers in northern and central India, combined with a usual heat wave, could influence cultivation.
• Seasonal spread improving: Last year's kharif was not good for the industry due to rainfall timing and distribution, so it cannot be taken as representative. As new products are introduced and PI expands into wheat and horticulture (Q2, Q3, Q4), there will be more spread across seasons, though kharif remains the major season for FY23.
• Structural tailwinds: Record crop prices and export-led growth are encouraging farmers to adopt modern crop protection techniques for maximized productivity. Management expects high double-digit domestic growth in FY23, with reasonably good growth in the first season based on positive preliminary monsoon and acreage indications.

Capex, Capacity & Asset Efficiency

• FY23 capex plan: Approximately ₹500 crore, covering maintenance, R&D, new technologies, and capacity equivalent to one to one-and-a-half multiproduct plants. FY24 capex is tentatively pegged at ₹350-400 crore, with a finer number expected later in the year.
• Brownfield expansion only: No greenfield plans at this point; management is considering brownfield projects in the current year or next. Existing sites (Jambusar, Ankleshwar, others) can accommodate the next two or three MPPs, providing at least a couple of years of expansion runway without acquiring new land.
• Asset turns as a differentiator: PI is already operating at more than 2x asset turns, exceeding the industry benchmark of 1.75-2x. Continuous efforts on the research side to improve processes, time cycles, and throughput, plus favorable product mix, drive this. Management sees scope to achieve better returns over the years and is working toward setting its own benchmarks.
• Capex is not the growth constraint: Growth is not linear with capex; a 10% improvement in efficiency or throughput effectively creates plant capacity. Management explicitly stated that capex is not the right benchmark in a process and technology business at the higher end of the value chain, unlike commodity chemicals where capacity and capital map directly to throughput.

Rajnish Sarna: "Well, to be honest, we are already kind of exceeding the benchmark. We were generally in this industry 1.75 - 2 is considered to be a reasonably good benchmark, but as you know, we are already doing better than that, and therefore, wanting to set our own benchmarks."

Inflation, Pricing & Risk Management

• Raw material pass-through nearly complete: The major part of raw material inflation has already been passed through; remaining products will be passed through in the next quarter. Each contract is different, and logistics is not a large proportion of cost given the value addition PI provides (it matters more for high-volume, commodity, low-value products).
• Inflation risk remains live: Management sees further risk of raw material increases in an inflationary trend and targets mitigation through pricing, optimizing product mix, and driving operational efficiencies.
• Capex inflation handled transparently: When capex costs increase significantly, management discusses this transparently with customers, and changes become part of revised plans and pricing structures. Customers generally consider these changes.
• Order book deliberately not stretched: The order book has remained around $1.4-1.5 billion despite 30-35% growth, because both PI and its customers are tentative about very long-term commitments given COVID, global supply chain volatility, and geopolitical conflicts. Management views the order book as having been relevant in early stages as risk management, but now stickiness from long-running products and capabilities makes it less of a driver.

Guidance & Commitments

Key Metrics